Revance Therapeutics — Investor Day (April 2018)
106 slides from Revance Therapeutics's investor day presentation, Apr 19, 2018
Slide 1: Revance 2018 Investor Day
REVANCE 2018 INVESTOR DAY APRIL 19, 2018 Exhibit 99.2
Slide 2: Forward-Looking Statements / Safe Harbor / Market Data
Forward-Looking Statements / Safe Harbor / Market Data This presentation contains forward-looking statements, including statements related to: our financial outlook and other financial performance; the process and timing of anticipated future clinical development of our product candidates; our busin
Slide 3: Welcome to Revance's First Investor Day Agenda
Welcome to Revance’s First Investor Day Agenda Revance Overview Remarkable Science Clinical Update Regulatory Panel Enduring Performance To Market We Go Market Analysis Market Realities – Expert Panel Revance Product Launch Velocity Q&A Summary and Close
Slide 4: Company Overview
COMPANY OVERVIEW DAN BROWNE President & CEO APRIL 19, 2018
Slide 5: The Vast Potential of Neuromodulators
$7B+ by 2024* … and 700+ Other Conditions * Source: Global Industry Analysts, Inc. Botulinum Toxin – A Global Strategic Business Report, Jan 2018 $4B+ TODAY* nasolabial folds wrinkles frown lines marionette lines rosacea acne neck lines crows feet depression heart trouble migraine foot pain urinary
Slide 6: The Challenge of Today's Neuromodulators
The Challenge of Today’s Neuromodulators Does it work as intended? EFFICACY Are there potential adverse side effects? SAFETY How long does it last before effect fades? DURATION Could it work BETTER? Higher response rates Could it last LONGER? ≥ 6 months vs. 3 months Could it be SAFER? Even at higher
Slide 7: Vision: Number One Neuromodulator in Any Form
Vision: Number One Neuromodulator in Any Form SAFETY HIGH RESPONSE RATES LONGER DURATION BETTER PATIENT OUTCOMES TEAM 1 HIGHLY EXPERIENCED TEAM WITH TRACK RECORD OF SUCCESS INNOVATOR IN NEUROMODULATION: Neuromodulator / Peptide Proprietary Formulations Novel Delivery Approaches SCIENCE 2 PERFORMANCE
Slide 8: DaxibotulinumtoxinA for Injection: The Beauty of RT002 Platform
DaxibotulinumtoxinA for Injection The Beauty of RT002 Platform First and only neuromodulator/peptide Exceptional stability, no animal/human excipients High response rates, long duration of effect Meets unmet need, significant global opportunity Global rights, expansive IP coverage RT002 is an invest
Slide 9: Our Two-Pronged Path, Aesthetics and Therapeutics
Our Two-Pronged Path, Aesthetics and Therapeutics LEVERAGE Infrastructure and EXPAND Therapeutic Pipeline THERAPEUTICS GAIN APPROVAL in Glabellar Lines and LAUNCH in Aesthetics AESTHETICS
Slide 10: Strategic Drivers for New Neuroscience Indications
Strategic Drivers for New Neuroscience Indications % of Sales of Neuromodulators by Indication – 2017E WW* Selection Criteria Largest segments Established markets Clear regulatory paths Targeted specialty segment Expanded New RT002 Neuroscience Pipeline Muscle Movement– ~$1.1BB Global Opportunity* C
Slide 11: Strategy: Commercialize in Aesthetics & Expand Neuroscience
Strategy: Commercialize in Aesthetics & Expand Neuroscience 2018 – 2021 2022 – 2025 2026+ COMMERCIAL LAUNCH ADVANCE PIPELINE ACCELERATE GROWTH Phase 3 in glabellar lines (open-label) & cervical dystonia & plantar fasciitis Phase 2 plantar fasciitis, upper limb spasticity & chronic migraine Phase 3 i
Slide 12: Unique Partnership to Develop and Commercialize Biosimilar to BOTOX
Unique Partnership to Develop and Commercialize Biosimilar to BOTOX® cGMP Facility Neurotoxin Expertise Production Technology Research to manufacturing R&D laboratories Experienced personnel Clinical development WW rights to Hall A strain Toxin gene cluster match Strong analytical capabilities US ba
Slide 13: Robust, Differentiated Pipeline
Robust, Differentiated Pipeline Biosimilar to BOTOX® Topical Preclinical Phase 1 Phase 2 Phase 3 RT002 AESTHETICS Glabellar Lines RT002 NEUROSCIENCE Cervical Dystonia Plantar Fasciitis Upper Limb Spasticity Chronic Migraine RT002 is an investigational product BOTOX is a registered trademark of Aller
Slide 14: Revance Product Launch Velocity: Objectives for Today
Revance Product Launch Velocity Plan and strategy to drive adoption Review mechanism and clinical data for long duration for daxi (RT002) across both aesthetic and therapeutic indications Examine the growing aesthetic market from clinical & commercial perspectives Provide update on daxi programs cur
Slide 15: Proven Team with Deep Experience & Expertise
Proven Team with Deep Experience & Expertise DAN BROWNE Co-Founder, President & CEO >30 years pharmaceutical and medical technology experience Various leadership roles in product development, sales and marketing ABHAY JOSHI, PH.D., M.B.A. COO >30 years global pharmaceutical and biotech experience in
Slide 16: Remarkable Science
REMARKABLE SCIENCE ABHAY JOSHI, Ph.D., M.B.A. Chief Operating Officer APRIL 19, 2018
Slide 17: Remarkable Science. Enduring Performance.
Remarkable Science. Enduring Performance.™ Technological Innovation Highly Differentiated Neuromodular/Peptide Technology Strong Operational Execution US-Based cGMP Manufacturing Facility On Track to File Glabellar Lines BLA in 1H2019 Aesthetic and Therapeutic Pipeline
Slide 18: RT002 Composition: Active Neurotoxin Type A
RT002 Composition: Active 150 kD Neurotoxin Type A from 900 kD Complex 900 kD Complex 150 kD Complex Accessory Proteins RT002 is an investigational product
Slide 19: RT002 Composition: 150 kD Naked Molecule
RT002 Composition: Active 150 kD Neurotoxin Type A from 900 kD Complex 900 kD Complex 150 kD Complex Accessory Proteins BoNT/A, 150 kDa ‘Naked’ Molecule Accessory Proteins 150 kD Complex No Animal-Derived Material Used in Processing RT002 is an investigational product
Slide 20: RT002 Composition: BoNT/A 150 kDa Molecule
RT002 Composition: Active 150 kD Neurotoxin Type A BoNT/A, 150 kDa ‘Naked’ Molecule RT002 is an investigational product
Slide 21: RT002 Composition: Proprietary Stabilizing Peptide Excipient
RT002 Composition: Proprietary Stabilizing Peptide Excipient Molecular Weight is approximately 5 kD Core poly-Lysines flanked at both ends by Protein Transduction Domain (PTD) Highly positively (+) charged amino acid sequence Peptide forms an electrostatic (noncovalent) charge interaction with BoNT-
Slide 22: Revance's Differentiated Neuromodulator Product
Revance’s Differentiated Neuromodulator Product 150 kD Neurotoxin type A Stabilizing Peptide Excipient Buffers, Sugar and Polysorbate 20 + + = DaxibotulinumtoxinA for Injection (RT002) RT002 RT002 is an investigational product
Slide 23: DaxibotulinumtoxinA Fundamentally Different Than Approved Products
DaxibotulinumtoxinA for Injection (RT002) Fundamentally Different Than Approved Products PRODUCT and PURITY Active Molecule Size 150 kD 900 kD Unknown 150 kD Free of Accessory Proteins ✓ ✕ ✕ ✓ SAFETY No Animal Derived Component ✓ ✕ ✕ ✕ No HSA (Human Serum Albumin) ✓ ✕ ✕ ✕ EFFICACY Higher Response Ra
Slide 24: Doubling the Dose Does Not Increase Duration of Effect
OnabotulinumtoxinA dose-ranging studies support 20U for women and 40U for men is ideal; however, there is no dose response or increase in duration beyond these doses For RT002, Duration of 24 weeks in Glabellar Lines and > 24 weeks in CD have been clinically demonstrated, and in the latter, duration
Slide 25: Nearly Equal Amount of Active Neurotoxin in Daxi 40U vs. Onabotulinum 20U
Nearly Equal Amount of Active Neurotoxin 150 kD Type A Present in DaxibotulinumtoxinA 40U vs. OnabotulinumtoxinA 20U* OnabotulinumtoxinA 20U 0.17† ng 150 kDa Neurotoxin DaxibotulinumtoxinA 40U 0.18 ng 150 kDa Neurotoxin *DaxibotulinumtoxinA 20U contains ~ 50% of the 150 kDa neurotoxin of Onabotulinu
Slide 26: Differentiating Capabilities
Differentiating Capabilities RESEARCH & DEVELOPMENT Neuromodulator focused expertise from basic research to product development Peptide research platform Modern analytical tools and cell based assays Fermentation/purification Biosimilar development REGULATORY Completed IND/EOP2 submissions with FDA/
Slide 27: Significant Investment in Commercial-Ready Manufacturing Facilities
Significant Investment in Commercial-Ready Manufacturing Facilities Located in the U.S. US Based Manufacturing for both Drug Substance and Drug Product State-of-the-Art Commercial-ready cGMP facility Drug Substance Capability to manufacture botulinum neurotoxin type A from 150 kD to 900 kD Drug Prod
Slide 28: Glabellar Lines US Regulatory Approval Process
DaxibotulinumtoxinA for Injection (RT002) Glabellar Lines US Regulatory Approval Process
Slide 29: Product Profile/Mechanism of Action
DaxibotulinumtoxinA for Injection (RT002) Product Profile/Mechanism of Action (MOA) Andreas Rummel, PhD - Senior Group Leader, Hannover Medical School, Hannover, Germany
Slide 30: Mechanism of Action: The Three A's of Peptide Function
RTP004 prevents Daxi from sticking to the vial (Adsorption) Mechanism of Action: The Three A’s of Peptide Function With RT002 Aggregation Adsorption Attraction Positively Charged Peptide Attraction Peptide forms an electrostatic (noncovalent) charge interaction with Daxi – the active pharmaceutical
Slide 31: Attraction: Proprietary Peptide and Daxi Interaction
Attraction: Proprietary Peptide and Daxi Interaction What Differentiates RT002 from Other Formulations? Peptide Supports a Net Positive Charge * Calculated by ExPASy pI/Mw tool BoNT/A 6.1 HSA 5.8 BoNT/A 6.1 Peptide 13.1* Revance’s Product RT002 Containing Peptide All Other Products Containing Human
Slide 32: Attraction: Proprietary Peptide Binds to Daxi
Attraction: Proprietary Peptide Binds to Daxi Surface Plasmon Resonance (SPR) Analysis Shows Daxi Binds to Immobilized Peptide But Not to HSA Time, Sec Daxi/Peptide 200 µg/mL Daxi/HSA 60 µg/mL 250 Response, RU 200 150 100 50 0 -50 -20 0 20 40 60 80 100 120 140 RT002 is an investigational product
Slide 33: Attraction: Peptide Enhances BoNT-A Membrane Binding
Attraction: Proprietary Peptide Enhances BoNT-A Membrane Binding Peptide Increases the Amount of Daxi (150 kDa) Binding to the Membrane Model 700 Binding level 1 600 500 400 300 200 3 5 Daxi only (100 µg/mL) 1:1 1:3 1:5 Peptide only (15 µg/mL) Daxi : Peptide Molar Ratio RT002 is an investigational p
Slide 34: Adsorption: Proprietary Peptide Minimizes Adsorption
Adsorption: Proprietary Peptide Minimizes Adsorption Peptide Minimizes Loss of Daxi and Potency Due to Container Surface Adsorption 0.30 0.25 0.20 0.15 0.10 0.05 0.00 Daxi content (ng/vial) p≤0.01 Peptide + PS-20 BoNT/A Content per Formulation PS-20 Only 70 50 40 30 20 10 0 Potency (U/vial) p≤0.01 P
Slide 35: Aggregation: Proprietary Peptide Minimizes Aggregation
Aggregation: Proprietary Peptide Minimizes Aggregation Stabilization of Daxi by Peptide Against Thermal Aggregation as Measured by Dynamic Light Scattering (DLS) less stable more stable Daxi alone Controls (no Daxi) Daxi + 0.05% PS-20 + 500 µg/mL HSA HSA control (dotted) - 0.05% PS-20 + 500 µg/ml HS
Slide 36: Role of Peptide in DaxibotulinumtoxinA for Injection
Revance’s proprietary peptide amino acid sequence is highly positively (+) charged Attraction: Peptide forms an electrostatic (noncovalent) charge interaction with Daxi – the active pharmaceutical ingredient (API; 150 kDa BoNT/A molecule) Adsorption: Peptide prevents Daxi from sticking to the vial s
Slide 37: Clinical Development Update
Clinical development Update Roman Rubio, M.D., Sr. Vice President, Clinical Development
Slide 38: Three Development Programs Currently Underway
Three Development Programs Currently Underway 1 SAKURA: GLABELLAR LINES Phase 3 Pivotal Program: Two Pivotal Studies + Open-Label Study AESTHETICS THERAPEUTICS 2 ASPEN: CERVICAL DYSTONIA 3 PLANTAR FASCIITIS Phase 3 Pivotal Program: One Pivotal Study + Open-Label Study Phase 2 Study Dose-Ranging, Pla
Slide 39: SAKURA Secondary Endpoint: None or Mild Response Rate Over Time
SAKURA 1 and 2 Secondary Endpoint None or Mild Response Rate on IGA-FWS and PFWS Over Time Robust Response Rates Observed on Key None or Mild Outcome Measure at All Time Points through Week 24 in Both Pivotal Studies Note: Cochran-Mantel-Haenszel test stratified by study center was used for response
Slide 40: SAKURA Results vs. BOTOX Cosmetic and Dysport USPI Data
SAKURA 1 and 2 Results BOTOX® Cosmetic and Dysport® USPI1 Data None or Mild Response Rates on 4-Point Investigator Assessment over Time 1United States Prescribing Information Phase 3 Studies in GL for each neuromodulator with data available through at least Day 120 conducted separately and presented
Slide 41: Median Duration of Effect in SAKURA 1 and 2
MEDIAN DURATION OF 24 WEEKS Time to Loss of None or Mild Wrinkle Severity in Both Pivotal Studies SAKURA 1 and 2 Efficacy Median Duration of at Least 24 Weeks Observed on Multiple Secondary Endpoints SAKURA 1 (n=201) SAKURA 2 (n=204) MEDIAN DURATION OF 26 WEEKS Time to Return to Baseline Wrinkle Sev
Slide 42: Example 2-Point Improvement Sustained Through Week 24
Example 2-Point Improvement by IGA-FWS & PFWS at Week 4 Two Point Sustained Duration of Effect through Week 24 Two point improvement from bassline on investigator and subject assessment IGA-FWS: 0 PFWS: 0 IGA-FWS: 0 PFWS: 0 IGA-FWS: 2 PFWS: 2 Week 4 Pre-Treatment Week 24 2 1 3 DaxibotulinumtoxinA 40
Slide 43: Example 1-Point Improvement Sustained Through Week 36
Example 2-Point Improvement by IGA-FWS & PFWS at Week 4 One Point Sustained Duration of Effect through Week 34 Week 32 Week 28 Week 36 Two point improvement from bassline on investigator and subject assessment DaxibotulinumtoxinA 40U – MAXIMUM FROWN IGA-FWS: 1 PFWS: 1 IGA-FWS: 1 PFWS: 2 IGA-FWS: 1 P
Slide 44: SAKURA Safety: Treatment-Related Adverse Events
SAKURA 1 and 2 Safety Number of Treatment-Related Adverse Events by Preferred Term (>2% in Any Arm) *6 cases of mild severity, 3 cases of moderate severity. All cases resolved without sequelae. Median duration of 58 days. **A placebo patient who received Daxi in error was included in the Daxi group
Slide 45: Cervical Dystonia: Largest Muscular Movement Disorder
Cervical Dystonia Largest Muscular Movement Disorder THE CONDITION Typically Treated by Neurologists Neuromodulator Retreatment Not More than Every 12 Weeks Painful and Debilitating Twisting Movements of Neck and Shoulders Currently available treatments and therapies include oral medications, botuli
Slide 46: Cervical Dystonia Phase 2 Duration of Effect
Cervical Dystonia Phase 2 Duration of > 24 Weeks Change from Baseline in TWSTRS-Total Score over Time Comparison of Reduction from Baseline in TWSTRS Total Score Between AbobotulinumtoxinA in Phase 3 Study and DaxibotulinumtoxinA in CL005 *Data approximated from Figure 2 of Poewe (2016): Efficacy an
Slide 47: Daxi for Isolated Cervical Dystonia Phase 2 Study
DaxibotulinumtoxinA Injection for Isolated Cervical Dystonia Phase 2 Dose Escalation Study Completed June 2016 RESULTS Efficacy: Median Duration of > 24 Weeks on TWSTRS-Total Scale Safety: Appeared to be generally safe and well-tolerated Study CL005 n = 37 Phase 3 Pivotal Study: Two Doses of Daxi vs
Slide 48: Cervical Dystonia ASPEN Phase 3 Program
Cervical Dystonia – ASPEN Phase 3 Program PIVOTAL PHASE 3 STUDY Designed to meet FDA regulatory requirements Study population: adult subjects with isolated cervical dystonia Two doses of Daxi for Injection studied vs. placebo Conducted at 75 study centers in US, Canada and Europe Primary Endpoint: C
Slide 49: Plantar Fasciitis: Highly Prevalent Foot/Heel Disorder
Plantar Fasciitis Highly Prevalent Foot/Heel Disorder THE CONDITION Typically Treated by Podiatrists, Physiatrists and Orthopedic Surgeons UNMET NEED No Neuromodulator Currently Approved to Treat Plantar Fasciitis Estimated to affect 11 to 18 million individuals in the U.S. 2M+ patients in U.S. unde
Slide 50: Plantar Fasciitis Phase 2 Results
Plantar Fasciitis Phase 2 results at Week 16 similar to Week 8 results Week 16 Results: Efficacy: Reduction from baseline in VAS-pain score of 58% observed with Daxi at Week 16; however strong placebo response also observed with no difference between treatment arms (p=0.42). Similar outcome observed
Slide 51: Adult Upper Limb Spasticity
Adult Upper Limb Spasticity Foundation Indication for Treatment of Dystonia UNMET NEED Spasms and Tightness of Muscles Caused by Stroke, MS, or Spinal Injuries Currently available treatments and therapies include oral medications, neuromodulators and intrathecal baclofen Significant unmet need exist
Slide 52: Chronic Migraine
Chronic Migraine >15 Headache Days per Month, 8 or More Days Feature Migraines* THE CONDITION Chronic Neurologic Disorder Primarily Treated by Neurologists Neuromodulator (BOTOX) Retreatment Required Every 12 Weeks UNMET NEED Migraine Is One of Most Prevalent Diseases in the World Affecting Almost 4
Slide 53: Regulatory Discussion Expert Panel
REGULATORY DISCUSSION Expert Panel Carmen Rodriguez - Regulatory Consultant Paul Lorenc, MD FACS - Aesthetic Plastic Surgery Susanne Fors, M. Sc. - Vice President Regulatory Affairs, Revance MODERATOR: Abhay Joshi, Ph.D., M.B.A., COO
Slide 54: Regulatory Panel: SAKURA and FDA Guidance
Regulatory Panel Susanne Fors In 2014, FDA issued Draft Guidance for Industry: Upper Facial Lines: Developing Botulinum Toxin Drug Products. Guidance covers Glabellar Lines, Forehead Lines and Lateral Canthal Lines. Can you comment on the conduct of SAKURA studies in context of the Upper Facial Line
Slide 55: Regulatory Panel: Clinically Meaningful Data
Regulatory Panel Dr. Paul Lorenc What data do you believe is the most clinically meaningful to physicians and patients from the SAKURA 1 and 2 studies?
Slide 56: SAKURA Results vs. BOTOX Cosmetic and Dysport USPI Data
SAKURA 1 and 2 Results BOTOX® Cosmetic and Dysport® USPI1 Data None or Mild Response Rates on 4-Point Investigator Assessment over Time 1United States Prescribing Information Phase 3 Studies in GL for each neuromodulator with data available through at least Day 120 conducted separately and presented
Slide 57: Median Duration of Effect in SAKURA 1 and 2
MEDIAN DURATION OF 24 WEEKS Time to Loss of None or Mild Wrinkle Severity in Both Pivotal Studies SAKURA 1 and 2 Efficacy Median Duration of at Least 24 Weeks Observed on Multiple Secondary Endpoints SAKURA 1 (n=201) SAKURA 2 (n=204) MEDIAN DURATION OF 26 WEEKS Time to Return to Baseline Wrinkle Sev
Slide 58: Regulatory Panel: Data Presentation for Secondary Endpoints
Regulatory Panel Carmen Rodriguez What would be the most compelling form of data presentation for Secondary Endpoints for DaxibotulinumtoxinA for Injection (Daxi) for Glabellar Lines label?
Slide 59: Regulatory Panel: Factors in Defining a Product Label
Regulatory Panel Carmen Rodriguez What are the key factors the FDA considers when defining a product label?
Slide 60: Regulatory Panel: Likely Daxi Label Features
Regulatory Panel Susanne Fors 5. What features will the final Daxi label for Glabellar Lines likely include?
Slide 61: SAKURA Results vs. BOTOX Cosmetic and Dysport USPI Data
SAKURA 1 and 2 Results BOTOX® Cosmetic and Dysport® USPI1 Data None or Mild Response Rates on 4-Point Investigator Assessment over Time 1United States Prescribing Information Phase 3 Studies in GL for each neuromodulator with data available through at least Day 120 conducted separately and presented
Slide 62: Enduring Performance: To Market We Go
ENDURING PERFORMANCE TO MARKET WE GO
Slide 63: Global Neuromodulator Market Overview
Global Neuromodulator market overview Daryl Bogard, Niche HealthCare Strategic Advisors, Inc.
Slide 64: Daryl Bogard, Niche HealthCare Strategic Advisors
Daryl Bogard Partner, Niche HealthCare Strategic Advisors Seamlessly transitioned from the corporate arena to the consulting world 30+ years pharmaceutical / medical device commercial experience Led AGN Global Marketing Research for >15 years in aesthetics & ophthalmology Areas of Expertise: Complex
Slide 65: US Accounts for 59% of Growing WW Neuromodulator Sales
The US Currently Accounts for 59% of the Growing WW Neuromodulator Sales Sources: AGN, analysts’ reports, EvaluatePharma, Galderma, Hugel, Ipsen, L'Oréal, Medytox, Merz, Nestle, syndicated reports, estimates 2010-2017 US$ CAGRs @ ARs WW = 12.6% (14% @ CERs) US = 15.7% Int’l = 9.1% (13% @ CERs) The U
Slide 66: Aesthetic Portion of WW Neuromodulator Sales Held Steady
The Aesthetic Portion of WW Neuromodulator Sales Has Held Steady at 47-48% the Last Eight Years Sources: AGN, analysts’ reports, EvaluatePharma, Galderma, Hugel, Ipsen, L'Oréal, Medytox, Merz, Nestle, syndicated reports, estimates Despite the popularity of BOTOX Cosmetic, therapeutic sales have alwa
Slide 67: Nine FDA Therapeutic Approvals for BOTOX Drove Growth
A Total of Nine FDA Therapeutic Approvals for BOTOX Have Helped Drive the Growth of the Therapeutic Neuromodulator Sales Sources: AGN, analysts’ reports, EvaluatePharma, Galderma, Hugel, Ipsen, L'Oréal, Medytox, Merz, Nestle, syndicated reports, estimates The gap between US and International Therape
Slide 68: Aesthetic Neuromodulator Sales and Growth Robust
Aesthetic Neuromodulator Sales and Growth Have Been Particularly Robust the Past Eight Years Sources: AGN, analysts’ reports, EvaluatePharma, Galderma, Hugel, Ipsen, L'Oréal, Medytox, Merz, Nestle, syndicated reports, estimates BOTOX Cosmetic FDA approved glabellar lines BOTOX Cosmetic approved crow
Slide 69: Future Growth Prospects Bright for All Segments
Future Growth Prospects Are Bright for All Segments of the Neuromodulator Market Projected Neuromodulator Sales US$ 5-Year CAGR, 2017-2022F Sources: Selected syndicated reports, estimates Projected Neuromodulator Sales US$ 5-Year CAGRs Therapeutic Aesthetic Total United States 13.5% 10.0% 12.2% Inte
Slide 70: Eylea's Dosing Schedule Helped Drive Anti-VEGF Share
Eylea’s Favorable Dosing Schedule Helped Drive Its US Branded Anti-VEGF US$ Share While Continuing to Expand the Market Sources: AAO, Bayer, EvaluatePharma, Novartis, Regeneron, Roche, Santen The differences between Eylea and Lucentis are considered clinically insignificant by many retina specialist
Slide 71: Global Neuromodulators Summary
Global Neuromodulators Summary The neuromodulator opportunity is substantial: therapeutic and aesthetic US and International Growth rates in all segments has been in double digits and is expected to continue Therapeutic sales will expand with current and additional indications Aesthetic sales are un
Slide 72: Market Realities Expert Panel
MARKET REALITIES Expert Panel Grant Stevens, MD, FACS, Marina Plastic Surgery and Orange Twist Institute Joely Kaufman, MD, FAAD, Skin Associates of South Florida Tom Seery, CEO/Founder, RealSelf Jodi Kaback, Facial Injectable Consumer Moderator: Todd Zavodnick CCO and President, Aesthetics & Therap
Slide 73: Grant Stevens, MD, FACS
Grant Stevens, MD, FACS Practice Dynamics Board-certified Plastic Surgeon Founder and Director of Marina Plastic Surgery and the Institute, Medical Director of Orange Twist Brands Chairman of the USC-Marina Aesthetic Surgery Fellowship and the Director of the USC Division of Aesthetic Surgery Clinic
Slide 74: Practice Offering Surgical Procedures, Injectables and Med Spa
Dedicated to Offering the Latest Advancements in Surgical Procedures and Injectables, Along with the Benefits of a Med Spa
Slide 75: Beauty for LIFE = Patient for LIFE
Beauty for LIFE = Patient for LIFE™ 25 years 45 years 35 years 55 years These slides include content directly from a third party
Slide 76: Beauty for LIFE Doesn't Have to Be a Burden to the Patient
Beauty for LIFE doesn’t have to be a burden to the patient Fillers, Neuromodulators, Laser Hair Removal Fillers, Neuromodulators, Laser Hair Removal Fillers, Neuromodulators, Laser Hair Removal Fillers, Neuromodulators, Laser Hair Removal Neuro- modulators Neuro- modulators 1 Year 1 Year Quality of
Slide 77: Key Questions Surrounding New Product Innovation in Aesthetics
Key questions surrounding new product innovation in aesthetics Product bundling & its ability to effect new entrants Longer duration products impacting practice revenue Introducing new innovation to “satisfied” consumers Breaking the consumer from the “household” name
Slide 78: Joely Kaufman, MD, FAAD: Longer-Acting Potential Use
Joely Kaufman, MD, FAAD Longer-Acting Potential Use Board-certified Dermatologist Private Practice in Coral Gables, Florida Voluntary Professor at University of Miami Director of Skin Research Institute Contributed to over 70 clinical trials in the dermatology space, with over 1/3 focusing on neurom
Slide 79: Skin Research Institute / My Practice
Skin Research Institute My Practice
Slide 80: Current Snapshot of Skin Associates Demographics
Current Snapshot of Skin Associates Demographics 12-18% CAGR Over the last 3 years 1% 4% 15% 39% <20 21-29 30-39 40-54 41% >55 89% Female 11% Male 85% onabotulinum toxin 1% incobotulinum toxin 14% abobotulinum toxin 1Skin Associates of South Florida Practice Data March 2018 These slides include cont
Slide 81: My Perspective on Common RT002 Questions
My perspective on common RT002 questions: What do you find most appealing about RT002? How would RT002 change my overall practice flow? How do you switch a consumer off of an established brand? Do I anticipate a negative impact on revenue, if I use RT002 due to competitive product bundles and less t
Slide 82: Digital Moves the Needle in Aesthetics
Digital moves the needle in aesthetics Tom Seery CEO/Founder Follow me on Instagram @realself @realself_tom
Slide 83: RealSelf Is the Leading Digital Marketplace in Aesthetics
RealSelf is the leading digital marketplace in aesthetics where millions of consumers and thousands of HCP’s come together to share what’s “worth it,” ask and deliver expert advice... ….and ultimately connect for treatment, offline.
Slide 84: Digital Is Central to Aesthetic Trends
Digital is central to aesthetic trends and how brands reach consumers Millions of cosmetic procedure posts 94 Million unique annual visitors to reviews, photos, Q&A, video Neuromodulator brand hashtags 2,820,051 posts These slides include content directly from a third party
Slide 85: 60% Conduct Plastic Surgery Research Online
60% conduct plastic surgery research online Sources: RealSelf Google Analytics, September 2016 through August 2017, American Academy of Facial Plastic and Reconstructive Surgery, RealSelf consumer survey, September 2014 49% say social media directly influenced consideration or decision to have cosme
Slide 86: Top Consumer Pain Points
Top 3 Consumer Pain Points Concerns about the outcome Finding the right provider Understanding what procedure is right Source: RealSelf consumer survey, 2017 It’s how consumers get answers These slides include content directly from a third party
Slide 87: It's Where HCPs Go to Grow Their Business
It’s where HCPs go to grow their business #plasticsurgery 1,323,015 posts #dermatology 559,044 posts # of new claimed provider profiles on realself 56% 2-year growth rate RealSelf claimed provider profiles Source: RealSelf internal data, 2017 These slides include content directly from a third party
Slide 88: Digital Amplifies Brand Awareness for Aesthetic Products
Digital is a key way to amplify and build brand awareness for aesthetic products 568 Posts on RealSelf 13 Posts by RealSelf on social media 390,713 Sessions on RealSelf.com 382,850 Impressions on RealSelf social media posts 1 Filler brand on RealSelf in Q1 These slides include content directly from
Slide 89: New Entrants with Digital-First Strategies
vs vs vs New entrants with digital-first strategies upend traditional ways to grow awareness and share These slides include content directly from a third party
Slide 90: Jodi Kaback, Facial Injectable Consumer
Jodi Kaback Facial Injectable Consumer Up Close & Personal Age: 47 Years Facial Injectable Use: 10 Years Neuromodulator and Dermal Fillers Profession: Event Planner/Fundraiser
Slide 91: Revance Product Launch Velocity
REVANCE PRODUCT LAUNCH VELOCITY TODD ZAVODNICK Chief Commercial Officer, President Aesthetics and Therapeutics APRIL 19, 2018
Slide 92: I don't believe in luck. I believe in preparation.
I don’t believe in luck. I believe in preparation. − Bobby Knight
Slide 93: Revance Product Velocity Launch Plan
REVANCE PRODUCT VELOCITY LAUNCH PLAN Building Momentum for Commercial Success MARKET ADOPTION NURTURING Relationships & Fostering Advocacy ASSEMBLING Commercial Operation BRANDING and Market Launch Preparations Underway To Drive
Slide 94: Our Focus
Our Focus SALES COMMERCIAL OPERATIONS MARKETING DIGITAL MARKETING Our Focus
Slide 95: Sales
SALES Revance Advocacy Program Commercial Policy Development HCP Consumer Sales Force Sizing Our Focus SALES COMMERCIAL OPERATIONS MARKETING DIGITAL MARKETING Our Focus
Slide 96: Foundation Marketing
FOUNDATION MARKETING Market Segmentation HCP/ Consumer Positioning Brand Identity Naming, Packaging Price Sensitivity Analysis Our Focus SALES COMMERCIAL OPERATIONS MARKETING DIGITAL MARKETING Our Focus
Slide 97: Digital Marketing
DIGITAL MARKETING Authentic Actively involved and building relationships with social communities and with the right partners Personalized Leveraging precise targeting, segmentation and personalization at scale Opportunistic Real-time intelligence and rapid response to capitalize on every opportunity
Slide 98: Born in Silicon Valley, We Think Differently
Born in Silicon Valley, WE THINK DIFFERENTLY. As a nimble startup, we will be MORE GENUINE, LESS BUREAUCRATIC, and REACT QUICKER than our competition. Digital Advantage Insight Gathering Relationship Building MarTech Infrastructure Social Campaigns Database Building Intelligence Gathering Hyper-targ
Slide 99: Commercial Operations
Our Focus SALES COMMERCIAL OPERATIONS MARKETING DIGITAL MARKETING Our Focus COMMERCIAL OPERATIONS Marketing Analytics Supply Chain Management Customer Relationship Management (CRM) Customer Service
Slide 100: RT002 Potential to Deliver on Most Important Unmet Need
RT002 Has the Potential to Be the First Neuromodulator to Deliver on the Most Important Physician Unmet Need and Patient Request PATIENTS If you could create the ideal treatment for fine lines and wrinkles, what would be the three most important things for it to have? (n=80) PHYSICIANS What are the
Slide 101: Sell-Side Research Supports RT002 Success
Sell-Side Research Supports RT002 Success New entrants will capture 33%-34% of the US market, with majority captured by Revance (18%). 100 High-Volume US Aesthetic Physician If a toxin lasted 24 weeks, 60% thought it could capture 50% or more of the market. 72% of patients would have high enthusiasm
Slide 102: Assembling a Commercial Team of Industry Veterans
Proven Team with Deep Experience Assembling a Commercial Team of Industry Veterans TODD ZAVODNICK CCO and President, Aesthetics & Therapeutics >20 years domestic and international sales and marketing experience Leadership roles overseeing aesthetics and eye care products/markets ERICA BAZERKANIAN VP
Slide 103: Questions and Answers
QUESTIONS AND ANSWERS Dan Browne, President and CEO
Slide 104: Investor Day Summary
INVESTOR DAY SUMMARY DAN BROWNE President & CEO
Slide 105: Closing Remarks
Closing Remarks * Source: Global Industry Analysts, Inc. Botulinum Toxin – A Global Strategic Business Report, Jan 2018 EXPANDing neuroscience Pipeline Cervical dystonia, plantar fasciitis, upper limb spasticity and chronic migraine REVANCE PRODUCT LAUNCH VELOCITY Aesthetics Ensuring preparation and
Slide 106: Thank You for Joining Us
THANK YOU FOR JOINING US DAN BROWNE President & CEO